[Risks associated with the use of non-steroidal anti-inflammatory drugs during pneumonia]

Abstract

Introduction: Outpatient treatment of community-acquired pneumonia (CAP) patients with non-steroidal anti-inflammatory drugs (NSAIDs) is frequent, although this is not based on clinical recommendations and there is no scientific evidence supporting better symptom relief in comparison to acetaminophen.

State of the art: Experimental data suggest that NSAIDs alter the intrinsic functions of neutrophils, limit their locoregional recruitment, alter bacterial clearance and delay the resolution of inflammatory processes during acute bacterial pulmonary challenge. In hospitalized children and adults with CAP, observational data suggest a strong and independent association between the outpatient exposure to NSAIDs and the occurrence of pleuropulmonary complications (pleural empyema, excavation, and abscess). In the only study taking into account possible protopathic bias, the association still persists. Other markers of morbidity have been described, including delay in hospital management, prolonged antibiotic therapy, and higher transfer rate to an intensive care unit.

Perspectives: Data describing the role of self-medication and the biological mechanisms involved are needed.

Conclusions: Intake of NSAIDs during outpatient treatment of CAP is probably the second modifiable factor of morbidity after inadequate antibiotic therapy. In light of existing data in children and adults, health authorities should urgently reassess the risk-benefit ratio of NSAIDS in CAP.

Keywords: Anti-inflammatoires non stéroïdiens; Community-acquired pneumonia; Empyème pleural; Iatrogenic diseases; Iatrogénie; Non-steroidal anti-inflammatory drugs; Pleural effusion; Pleural empyema; Pleurésie; Pneumonia; Pneumonie; Pneumopathie infectieuse.